Galapagos NV Appoints Dr. Paul Stoffels as New CEO
Ticker: GLPGF · Form: 6-K · Filed: May 30, 2024 · CIK: 1421876
| Field | Detail |
|---|---|
| Company | Galapagos NV (GLPGF) |
| Form Type | 6-K |
| Filed Date | May 30, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, ceo-appointment, biotech
Related Tickers: GLPG
TL;DR
Galapagos NV just named Dr. Paul Stoffels, ex-J&J CSO, as their new CEO, replacing Adrian Rawcliffe.
AI Summary
On May 30, 2024, Galapagos NV announced the appointment of Dr. Paul Stoffels as Chief Executive Officer, effective immediately. He succeeds Adrian Rawcliffe. Dr. Stoffels brings extensive experience in the pharmaceutical industry, having previously served as Executive Vice President and Chief Scientific Officer at Johnson & Johnson.
Why It Matters
The leadership change at Galapagos NV, a biopharmaceutical company, could signal a shift in strategic direction and focus for its drug development pipeline.
Risk Assessment
Risk Level: medium — Leadership changes in biopharmaceutical companies can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Galapagos NV (company) — Registrant
- Dr. Paul Stoffels (person) — Appointed CEO
- Adrian Rawcliffe (person) — Previous CEO
- May 30, 2024 (date) — Announcement date
- Johnson & Johnson (company) — Dr. Stoffels' previous employer
FAQ
Who has been appointed as the new CEO of Galapagos NV?
Dr. Paul Stoffels has been appointed as the new CEO of Galapagos NV.
When was the announcement of the new CEO made?
The announcement was made on May 30, 2024.
Who is Dr. Paul Stoffels succeeding as CEO?
Dr. Paul Stoffels is succeeding Adrian Rawcliffe as CEO.
What was Dr. Paul Stoffels' previous role?
Dr. Paul Stoffels previously served as Executive Vice President and Chief Scientific Officer at Johnson & Johnson.
What form was this announcement filed under?
This announcement was filed as a Form 6-K.
Filing Stats: 224 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-05-30 16:44:37
Filing Documents
- f6k_053024.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 13KB
- 0001171843-24-003174.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GALAPAGOS NV (Registrant) Date: May 30, 2024 /s/ Annelies Denecker Annelies Denecker Company Secretary